Methods of inhibiting CXC intercrine molecules
US5965536A · kind A · utility
16Cited by
1References
59Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 1996 |
| Grant date | Oct 12, 1999 |
| Priority date | — |
| Expiry date | Jun 14, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for inhibiting and modulating the actions of CXC intercrine molecules. The antileukinate peptides described inhibit IL-8, GRO and MIP2.beta. binding to neutrophils and neutrophil activation. The peptides are particularly advantageous as they inhibit IL-8-induced enzyme release at a 25 fold lower concentration than is required to inhibit chemotaxis, which makes them ideal for treating various inflammatory diseases and disorders including, amongst others, Adult Respiratory Distress Syndrome (ARDS), cystic fibrosis and chronic bronchitis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.